Evaluating current manufacturing platforms for recombinant AAV production


Realizing the full potential of viral vector-based therapies requires a successful manufacturing platform for recombinant Adeno-associated virus (AAV) vectors. As one explores different AAV options, it is important to understand the platforms used in the industry today and properly evaluate their fitness for your molecule’s unique needs.

In this whitepaper, you’ll walk through a comparison of the different AAV platforms and their pros and cons to help evaluate which AAV option is best suited for your gene therapy.